Urocortin and cardiovascular protection

Acta Pharmacologica Sinica

Volumn 25, Issue 3, 2004, Pages 257-265

  Huang, Yu ^a   Yao, Xiao Qiang ^a   Lau, Chi Wai ^a   Chan, Yau Chi ^a   Tsang, Suk Ying ^a   Chan, Franky Leung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Corticotropin releasing hormone; Heart; Protein kinases; Second messenger system; Urocortin; Vascular smooth muscle; Vasodilaion

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; POLYPEPTIDE; UNCLASSIFIED DRUG; UROCORTIN;

AMINO ACID SEQUENCE; CARDIOVASCULAR SYSTEM; HEART FUNCTION; HEART PROTECTION; HORMONE ACTION; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SECOND MESSENGER; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRESS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CARDIOTONIC AGENTS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; VASODILATOR AGENTS;

EID: 1542314291     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92.
2. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, et al. Cloning and characterization of human urocortin. Endocrinology 1996; 137: 2167-70.
3. Zhao L, Donaldson CJ, Smith GW, Vale WW. The structures of the mouse and human urocortin genes (Ucn and UCN). Genomics 1998; 50: 23-33.
4. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7: 605-11.
5. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001; 98: 7570-5.
6. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001; 98: 2843-8.
7. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, et al. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 2000; 279: H3031-9.
8. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, et al. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002; 87: 340-6.
9. Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J. Molecular biology of the CRH receptors - in the mood. Peptides 2001; 22: 753-60.
10. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, et al. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 1994; 91: 8777-81.
11. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995; 92: 836-40.
12. Lovenberg TW, Chalmers DT, Liu C, De Souza EB. CRF2a and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995; 136: 4139-42.
13. Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci USA 1995; 92: 2969-73.
14. Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993; 90: 8967-71.
15. Stenzel P, Kesterson R, Yeung W, Cone RD, Rittenberg MB, Stenzel-Poore MP. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995; 9: 637-45.
16. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23: 71-7.
17. Rossant CJ, Pinnock RD, Hughes J, Hall MD, McNulty S. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3′, 5′-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology 1999; 140: 1525-36.
18. Leitch IM, Boura AL, Botti C, Read MA, Walters WA, Smith R, et al. Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro. J Clin Endocrinol Metab 1998; 83: 4510-3.
19. Sanz E, Monge L, Fernandez N, Martinez MA, Martinez-Leon JB, Dieguez G, et al. Relaxation by urocortin of human saphenous veins. Br J Pharmacol 2002; 136: 90-4.
20. Schilling L, Kanzler C, Schmiedek P, Ehrenreich H. Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery. Br J Pharmacol 1998; 125: 1164-71.
21. Lubomirov L, Gagov H, Petkova-Kirova P, Duridanova D, Kalentchuk VU, Schubert R. Urocortin relaxes rat tail arteries by a PKA-mediated reduction of the sensitivity of the contractile apparatus for calcium. Br J Pharmacol 2001; 134: 1564-70.
22. + channels. Br J Pharmacol 2002; 135: 1467-76.
23. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 1997; 272: H2115-22.
24. Jain V, Longo M, Ali M, Saade GR, Chwalisz K, Garfield RE. Expression of receptors for corticotropin-releasing factor in the vasculature of pregnant rats. J Soc Gynecol Investig 2000; 7: 153-60.
25. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24: 410-4.
26. Jain V, Vedernikov YP, Saade GR, Chwalisz K, Garfield RE. Endothelium-dependent and -independent mechanisms of vasorelaxation by corticotropin-releasing factor in pregnant rat uterine artery. J Pharmacol Exp Ther 1999; 288: 407-13.
27. Jain V, Vedernikov YP, Saade GR, Chwalisz K, Garfield RE. The relaxation responses to corticotropin-releasing factor in rat aorta are endothelium dependent and gestationally regulated. Am J Obstet Gynecol 1997; 176: 234-40.
28. Grunt M, Glaser J, Schmidhuber H, Pauschinger P, Born J. Effects of corticotropin-releasing factor on isolated rat heart activity. Am J Physiol 1993; 264: H1124-9.
29. Clifton VL, Read MA, Leitch IM, Giles WB, Boura AL, Robinson PJ, et al. Corticotropin-releasing hormone-induced vasodilatation in the human fetal-placental circulation: involvement of the nitric oxide-cyclic guanosine 3′,5′-monophosphate-mediated pathway. J Clin Endocrinol Metab 1995; 80: 2888-93.
30. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. J Endocrinol 2001; 169: 177-83.
31. Kageyama K, Suda T. Regulation of corticotropin-releasing factor receptor type 2β messenger ribonucleic acid by interleukin-1β in rat vascular smooth muscle cells. Neuroimmunomodulation 2001; 9: 326-32.
32. + channels in endothelium-independent relaxation by urocortin in the rat coronary artery. Cardiovasc Res 2003; 57: 824-33.
33. Langton PD, Nelson MT, Huang Y, Standen NB. Block of calcium-activated potassium channels in mammalian arterial myocytes by tetraethylammonium ions. Am J Physiol 1991; 260: H927-34.
34. + channels in arterial smooth muscle. Science 1989; 245: 177-80.
35. + currents. J Muscle Res Cell Motil 2000; 21: 639-45.
36. Watanabe F, Oki Y, Ozawa M, Masuzawa M, Iwabuchi M, Yoshimi T, et al. Urocortin in human placenta and maternal plasma. Peptides 1999; 20: 205-9.
37. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351-62.
38. Singh LK, Boucher W, Pang X, Letourneau R, Seretakis D, Green M, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther 1999; 288: 1349-56.
39. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI, et al. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. J Clin Endocrinol Metab 2001; 86: 4344-52.
40. Heldwein KA, Redick DL, Rittenberg MB, Claycomb WC, Stenzel-Poore MP. Corticotropin-releasing hormone receptor expression and functional coupling in neonatal cardiac myocytes and AT-1 cells. Endocrinology 1996; 137: 3631-9.
41. Parkes DG, Weisinger RS, May CN. Cardiovascular actions of CRH and urocortin: an update. Peptides 2001; 22: 821-7.
42. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24: 403-9.
43. Brar BK, Stephanou A, Wagstaff MJ, Coffin RS, Marber MS, Engelmann G, et al. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress. J Mol Cell Cardiol 1999; 31: 135-46.
44. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000; 275: 8508-14.
45. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002; 40: 1495-505.
46. Richter RM, Mulvany MJ. Comparison of hCRF and oCRF effects on cardiovascular responses after central, peripheral, and in vitro application. Peptides 1995; 16: 843-9.
47. Hermus AR, Pieters GF, Willemsen JJ, Ross HA, Smals AG, Benraad TJ, et al. Hypotensive effects of ovine and human corticotrophin-releasing factors in man. Eur J Clin Pharmacol 1987; 31: 531-4.
48. Udelsman R, Gallucci WT, Bacher J, Loriaux DL, Chrousos GP. Hemodynamic effects of corticotropin releasing hormone in the anesthetized cynomolgus monkey. Peptides 1986; 7: 465-71.
49. Parkes D, May C. Cardiac and vascular actions of urocortin. In: Share L, editors. Hormones and Heart in Health and Disease. 1999. p 39-52.
50. Oki Y, Iwabuchi M, Masuzawa M, Watanabe F, Ozawa M, Iino K, et al. Distribution and concentration of urocortin, and effect of adrenalectomy on its content in rat hypothalamus. Life Sci 1998; 62: 807-12.
51. Okosi A, Brar BK, Chan M, D'Souza L, Smith E, Stephanou A, et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides 1998; 32: 167-71.
52. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-9.
53. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 1999; 274: 6272-9.
54. Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM, Dillmann WH. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 1995; 95: 1446-56.
55. Plumier JC, Ross BM, Currie RW, Angelidis CE, Kazlaris H, Kollias G, et al. Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 1995; 95: 1854-60.
56. Hutter JJ, Mestril R, Tam EK, Sievers RE, Dillmann WH, Wolfe CL. Overexpression of heat shock protein 72 in transgenic mice decreases infarct size in vivo. Circulation 1996; 94: 1408-11.
57. Radford NB, Fina M, Benjamin IJ, Moreadith RW, Graves KH, Zhao P, et al. Cardioprotective effects of 70-kDa heat shock protein in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 2339-42.
58. Brar BK, Railson J, Stephanou A, Knight RA, Latchman DS. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol 2002; 172: 283-93.
59. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem 2000; 275: 10002-8.
60. Stephanou A, Scarabelli TM, Townsend PA, Bell R, Yellon D, Knight RA, et al. The C-terminal activation domain of the STAT-1 transcription enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes. FASEB J 2002; 16: 1841-3.
61. Kuwahara K, Saito Y, Kishimoto I, Miyamoto Y, Harada M, Ogawa E, et al. Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol 2000; 32: 1385-94.
62. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104: 330-5.
63. Aikawa R, Nawano M, Gu Y, Katagiri H, Asano T, Zhu W, et al. Insulin prevents cardiomyocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation 2000; 102: 2873-9.
64. Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 2002; 34: 483-92.
65. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 12333-8.
66. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002; 22: 2799-809.
67. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol 2002; 40: 155-61.
68. Akao M, Ohler A, O'Rourke B, Marban E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 2001; 88: 1267-75.
69. Akao M, Teshima Y, Marban E. Antiapoptotic effect of nicorandil mediated by mitochondrial ATP-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol 2002; 40: 803-10.
70. ATP channel gene expression is induced by urocortin and mediates its cardioprotective effect. Circulation 2002; 106: 1556-62.
71. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 1997; 272: 5783-91.
72. Brar BK, Stephanou A, Pennica D, Latchman DS. CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 2001; 16: 93-6.
73. Ikeda K, Tojo K, Sato S, Ebisawa T, Tokudome G, Hosoya T, et al. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 1998; 250: 298-304.
74. Ikeda K, Tojo K, Oki Y, Nakao K. Urocortin has cell-proliferative effects on cardiac non-myocytes. Life Sci 2002; 71: 1929-38.